Medexus Pharmaceuticals Schedules Second Quarter Fiscal 2021 Conference Call
November 09 2020 - 7:30AM
Medexus Pharmaceuticals Inc. (the
“Company” or “Medexus)
(TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today
announced that it plans to host a conference call at 8:00 AM
Eastern Time on Tuesday, November 17, 2020 to discuss the Company’s
financial results for the fiscal 2021 second quarter ended
September 30, 2020, as well as the Company’s corporate progress and
other developments. The Company expects to file its financial
statements along with its MD&A post market on November 16,
2020.
The conference call will be available via
telephone by dialing toll free 844-369-8770 for Canadian and U.S.
callers or +1 862-298-0840 for international callers, or on the
Company’s Investor Events section of the
website: https://www.medexus.com/en_US/investors/news-events.
A webcast replay will be available on the
Company’s Investor Events section of the website
(https://www.medexus.com/en_US/investors/news-events) through
Wednesday, February 17, 2021. A telephone replay of the call will
be available approximately one hour following the call, through
Tuesday, November 24, 2020 and can be accessed by dialing
877-481-4010 for Canadian and U.S. callers or +1 919-882-2331 for
international callers and entering conference ID: 38655.
About Medexus
Pharmaceuticals Inc.
Medexus is a leading specialty pharmaceutical
company with a strong North American commercial platform. The
Company’s vision is to provide the best healthcare products to
healthcare professionals and patients, through our core values of
Quality, Innovation, Customer Service and Teamwork. Medexus
Pharmaceuticals is focused on the therapeutic areas of auto-immune
disease, hematology and allergy. The Company’s leading products
are: Rasuvo™ and Metoject®, a unique formulation of methotrexate
(auto-pen and pre-filled syringe) designed to treat rheumatoid
arthritis and other auto-immune diseases; IXINITY®, an intravenous
recombinant factor IX therapeutic for use in patients 12 years of
age or older with Hemophilia B – a hereditary bleeding disorder
characterized by a deficiency of clotting factor IX in the blood,
which is necessary to control bleeding; and Rupall®, an innovative
prescription allergy medication with a unique mode of action.
For more information, please
contact:
Ken d’Entremont, Chief Executive OfficerMedexus
Pharmaceuticals Inc.Tel.: 905-676-0003E-mail:
ken.dentremont@medexus.com
Roland Boivin, Chief Financial OfficerMedexus
Pharmaceuticals Inc.Tel.: 514-762-2626 ext. 202E-mail:
roland.boivin@medexus.com
Investor Relations
(U.S.):Crescendo Communications, LLCTel:
+1-212-671-1020Email: mdp@crescendo-ir.com
Investor Relations
(Canada):Tina ByersAdelaide CapitalTel:
905-330-3275E-mail: tina@adcap.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jul 2023 to Jul 2024